8月22日，乐普生物-B(02157)盘中上涨6.16%，截至11:47，报10.17元/股，成交2.0亿元。
乐普生物科技股份有限公司主要市场在中国，专注于肿瘤治疗领域的生物制药研发，特别在靶向治疗及免疫治疗上有创新成果。该公司拥有完整的药物发现、临床开发、CMC及GMP合规生产的端到端能力，并已经建立了专业的销售和营销团队，旨在满足临床需求，提供优化和创新的药物解决方案。
截至2025年中报，乐普生物-B营业总收入4.66亿元、净利润4174.5万元。
8月20日，2025财年中报归属股东应占溢利4175万人民币，同比增长121.69%，基本每股收益0.02人民币。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.